The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).
Ines Maria Vaz Duarte Luis
No relevant relationships to disclose
Rebecca A Ottesen
No relevant relationships to disclose
Melissa E Hughes
No relevant relationships to disclose
Rizvan Mamet
No relevant relationships to disclose
Harold J. Burstein
No relevant relationships to disclose
Stephen B. Edge
No relevant relationships to disclose
Ana M. Gonzalez-Angulo
No relevant relationships to disclose
Sara H. Javid
No relevant relationships to disclose
Beverly Moy
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose
Richard L. Theriault
No relevant relationships to disclose
Jane C. Weeks
No relevant relationships to disclose
Nancy U. Lin
No relevant relationships to disclose